10-K/A: Ultralife Corporation Files Amendment No. 1 to Form 10-K, Providing Additional Corporate Governance and Executive Compensation Details

Ultralife Corporation files an amendment to its annual report on Form 10-K to include information on directors, executive officers, corporate governance, and executive compensation.

Summary

• Ultralife Corporation filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The amendment includes information previously omitted regarding Items 10 through 14 of Part III and amends Item 15 of Part IV and the Index of Exhibits of the Original Form 10-K.
• The original omission was due to reliance on General Instruction G(3) to Form 10-K, which allows incorporation by reference from the definitive proxy statement if filed within 120 days after the fiscal year-end.
• The company will not file a definitive proxy statement within that timeframe and is including the Part III information in this amendment.
• The definitive proxy statement is planned for filing on or about May 27, 2025, with the Annual Stockholders Meeting scheduled for July 16, 2025.
• The amendment restates Part III, Items 10 through 14, and Part IV, Item 15 of the Original Form 10-K in their entirety.
• The document includes new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
• The amendment does not modify any financial or other information in the Original Form 10-K or reflect events subsequent to its filing date.
• As of April 25, 2025, the registrant had 16,632,965 shares of common stock outstanding.
• On June 30, 2024, the aggregate market value of the common stock held by non-affiliates was approximately $107,463,992.
• The document details information about the company's directors, executive officers, corporate governance practices, executive compensation, and security ownership.
• The annual cash retainer for non-employee directors is $73,500, while the Board Chair receives $108,000 for the period July 1, 2024, through June 30, 2025.
• The company's short-term incentive plan (STIP) for 2024 had target bonus levels for Messrs. Manna and Fain at 60% and 50% of their respective base salaries, based on consolidated operating profit and revenue goals of $12.0 million and $169.5 million, respectively; however, these goals were not met, and no STIP awards were earned for 2024.
• The company's audit fees for 2024 were $1,194,028, and audit-related fees were $184,800.

Sentiment

Score: 6

Explanation: The document is primarily factual, providing details on corporate governance, executive compensation, and related matters. The sentiment is neutral, with some negative aspects related to not achieving STIP goals offset by positive aspects of corporate governance practices.

Positives

• The company has a Code of Ethics applicable to all employees and directors, emphasizing legal and ethical business conduct.
• The company has an Insider Trading Compliance Policy to prevent illegal trading activities.
• The Board of Directors has standing committees for Audit and Finance, Corporate Development and Governance, and Compensation and Management.
• The company provides a tax-qualified 401(k) plan to all active employees with employer matching contributions.
• The company has stock ownership guidelines for non-employee directors, requiring them to maintain ownership of at least $40,000 of common stock.

Negatives

• The company's STIP performance goals for 2024 were not achieved, resulting in no bonus awards for named executive officers.
• The company's consolidated operating profit and revenue goals of $12.0 million and $169.5 million, respectively, were not met in 2024.
• The company's audit fees increased significantly from $565,700 in 2023 to $1,194,028 in 2024.

Risks

• Failure to comply with the Insider Trading Compliance Policy could result in severe criminal and civil penalties for individuals and the company.
• Cybersecurity incidents could pose a material risk to the company's financial condition and operations.
• The company's reliance on key personnel, such as the President and CEO and CFO, could pose a risk if they were to leave the company.
• The company's ability to attract and retain qualified directors and executive officers is crucial for its success.
• The company's exposure to financial risks could have a material impact on its operations.

Future Outlook

The company plans to file its definitive proxy statement on or about May 27, 2025, and hold its 2025 Annual Stockholders Meeting on July 16, 2025.

Management Comments

• The Board of Directors believes that the segregation of the roles of Board Chair from that of the President and Chief Executive Officer ensures better overall governance of our Company and provides meaningful checks and balances regarding our overall performance.
• The Company is committed to a Board of Directors comprised of individuals with diverse backgrounds, skills and experiences.

Industry Context

The document provides insights into Ultralife Corporation's corporate governance practices, executive compensation structure, and risk management approach, which are common considerations for companies in the technology and manufacturing sectors.

Comparison to Industry Standards

• The document mentions surveying peer group companies to ascertain whether the overall director compensation is appropriate and balanced.
• The company aims to deliver annual director compensation at the median levels of director compensation for companies in similar industries and of similar size.
• The document references NASDAQ listing standards for director independence and committee composition.
• The company's executive compensation program is designed to align the interests of executives with those of stockholders, which is a common practice in publicly traded companies.
• The document mentions the use of stock options and other equity awards to incentivize executives, which is a standard practice in the industry.

Stakeholder Impact

• The document provides information relevant to shareholders regarding corporate governance, executive compensation, and security ownership.
• The company's Code of Ethics and Insider Trading Compliance Policy aim to protect the interests of stakeholders by promoting ethical business conduct and preventing illegal trading activities.
• The company's risk management approach is intended to mitigate potential risks that could impact stakeholders.

Next Steps

• Filing of the definitive proxy statement on or about May 27, 2025.
• Holding the 2025 Annual Stockholders Meeting on July 16, 2025.

Key Dates

Keywords

corporate governance, executive compensation, directors, financial reporting, Ultralife Corporation, Form 10-K, Amendment